Literature DB >> 8221360

Reversal of diastolic dysfunction by intravenous magnesium chloride.

F Kraus.   

Abstract

OBJECTIVE: To treat diastolic dysfunction in patients with coronary artery disease (CAD).
DESIGN: Open study of the intravenous injection of 5 mL of a solution containing 17% magnesium chloride (equal to 100 mg of elemental magnesium) during routine coronary angiography in patients with a raised left ventricular end-diastolic pressure (LVEDP).
SETTING: A hospital department of cardiac hemodynamics.
SUBJECTS: Ten patients with angiographically documented CAD.
RESULTS: After magnesium chloride injection, the LVEDP was significantly reduced in all patients, from a mean of 24 +/- 3 to 16 +/- 3 mmHg (P < 0.001).
CONCLUSIONS: Under the short term conditions of the study, the injection of magnesium chloride effectively improved left ventricular diastolic function. Further study of the long term effect is required.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221360

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  3 in total

1.  Nesiritide for treatment of perioperative low cardiac output syndromes in cardiac surgical patients: an initial experience.

Authors:  George R Gordon; Roman Schumann; Hassan Rastegar; Kamal Khabbaz; Michael R England
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

2.  Relation of Magnesium Intake With Cardiac Function and Heart Failure Hospitalizations in Black Adults: The Jackson Heart Study.

Authors:  Tracey H Taveira; Danielle Ouellette; Alev Gulum; Gaurav Choudhary; Charles B Eaton; Simin Liu; Wen-Chih Wu
Journal:  Circ Heart Fail       Date:  2016-04       Impact factor: 8.790

3.  Relationship Between Dietary Magnesium Intake and Incident Heart Failure Among Older Women: The WHI.

Authors:  Wen-Chih Wu; Mengna Huang; Tracey H Taveira; Mary B Roberts; Lisa W Martin; Gregory A Wellenius; Karen C Johnson; JoAnn E Manson; Simin Liu; Charles B Eaton
Journal:  J Am Heart Assoc       Date:  2020-03-20       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.